( MENAFN - GlobeNewsWire - Nasdaq) SOUTH SAN FRANCISCO, Calif., June 02, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or“the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today presented data from its Phase 1 ASPEN-07 clinical trial in a poster presentation (abstract #4575) at the 2024 American Society of Cancer Oncology (“ASCO”) Annual Meeting being held in Chicago from May 31-June 4, 2024.
These findings represent the first evorpacept combination data with an ADC from ASPEN-07's ongoing, open-label, single-arm, clinical trial of evorpacept in combination with PADCEV (enfortumab vedotin or“EV”) in patients with locally advanced or metastatic urothelial cancer (“la/m UC”). Evorpacept is a CD47 blocker with an inactivated Fc effector domain that is designed to minimize associated toxicity. Key results as of the data cut-off date of April 3, 2024: Initial patient demographics The combination was generally well-tolerated in a heavily pre-treated patient population Initial activity showed tumor reduction in the majority of evaluable patients “We are encouraged by the preliminary safety data and clinical activity of evorpacept combined with PADCEV in patients with advanced bladder cancer,” said Sophia Randolph, M.
D., Ph.D.
, Chief Medical Officer of ALX Oncology.“To our knowledge, these data are the first demonstration of anti-tumor activity with a CD47 block.
